Workflow from Scientific Research

BR.36 reached its target enrollment of 50 patients; for each individual, serial radiographic assessments and liquid biopsy analyses were performed. C1D1 plasma was collected for all 50 patients; C1D1 and C2D1 plasma samples were collected for 45 patients; and plasma samples were collected for all three timepoints for 39 patients. Five patients were deemed not evaluable because of missed plasma collection or non-evaluable RECIST assessments. Of the 45 evaluable patients, 10 had undetectable ctDNA at all timepoints (no tumor-specific plasma variants detected), resulting in 35 patients with evaluable ctDNA and RECIST responses.

DOI